Gopinath Nagaraj | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Luana Fioriti | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Luana Fioriti | Pharmacology | Best Researcher Award

Laboratory Director at Istiuto di Riceerche Farmacologiche Mario Negri | Italy

Assoc. Prof. Dr. Luana Fioriti is a distinguished neuroscientist recognized for her groundbreaking research on prion-like proteins, synaptic plasticity, and neurodegenerative disorders. She has served in leading roles at Columbia University and the “Mario Negri” Institute in Milan, where she heads her laboratory in the Department of Neuroscience. With extensive expertise in protein aggregation, memory mechanisms, and disease-related pathways, Dr. Fioriti has contributed significantly to advancing knowledge in molecular neuroscience. Her pioneering work has been published in leading scientific journals and supported by prestigious awards and fellowships. She continues to drive innovation in translational neurobiology research.

Publication Profile 

Orcid

Education 

Assoc. Prof. Dr. Luana Fioriti earned her PhD in Neuroscience at the Mario Negri Institute and Open University, Italy, where she investigated abnormal forms of prion proteins in inherited prion diseases. She completed a Master’s in Biotechnological Applications at the University of Milan with summa cum laude honors, and a degree in Biological Sciences, majoring in Molecular Biology, also with summa cum laude, from the same university. Early in her career, she trained at the Mario Negri Institute’s Laboratory of Neurodegenerative Disorders, under Dr. Gianluigi Forloni, where she developed her expertise in prion biology, neurotoxicity, and mechanisms underlying neurodegenerative diseases.

Experience 

Assoc. Prof. Dr. Luana Fioriti has held prominent academic and research positions in both Italy and the United States. She currently serves as Head of Laboratory at the Department of Neuroscience, Mario Negri Institute, Milan, and Adjunct Associate Research Scientist at Columbia University. She has conducted extensive work in the laboratories of Nobel Laureate Eric Kandel and Dr. Ottavio Arancio at Columbia. Previously, she was an Associate Research Scientist at the Howard Hughes Medical Institute. Her career reflects a consistent focus on molecular neuroscience, protein biology, and translational approaches to neurodegenerative disorders, combining leadership, mentorship, and cross-institutional scientific collaboration.

Awards and Honors 

Assoc. Prof. Dr. Luana Fioriti has been recognized with numerous fellowships and awards for her contributions to neuroscience. Early in her career, she received fellowships from the University of Milan, the Italian Institute for University Study, and the Mario Negri Institute. She was awarded a scholarship to present at the World Alzheimer Congress and fellowships from Fondazione Monzino and the Italian Academy for Advanced Studies at Columbia University. She earned the Columbia Mentorship Award, the Telethon Career Development Award, and the AIMS Award for identifying SARS-CoV-2 protein inhibitors. These honors highlight her outstanding research leadership and impact in neurobiology.

Research Focus 

Assoc. Prof. Dr. Luana Fioriti research focuses on the molecular mechanisms of neurodegenerative diseases and memory persistence, with a particular emphasis on prion-like proteins, SUMOylation, ubiquitination, and tau pathology. Her work explores how protein aggregation and regulation influence synaptic plasticity and memory storage, contributing to both normal physiology and disease pathology. She has advanced understanding of prion biology, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Through translational neuroscience, she investigates SUMO mimetics and small molecules as therapeutic candidates for dementia and other neurodegenerative disorders. Her research integrates cell models, animal systems, and cutting-edge molecular approaches to identify potential drug targets.

Publication Top Notes

Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin

SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2

Structure of a reversible amyloid fibril formed by the CPEB3 prion-like domain reveals a core sequence involved in translational regulation

A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo

Liquid-Liquid Phase Separation in Physiology and Pathophysiology of the Nervous System

Ubiquitination and SUMOylation of amyloid and amyloid-like proteins in health and disease

Neuronal Localization of SENP Proteins with Super Resolution Microscopy

CPEB3 inhibits translation of mRNA targets by localizing them to P bodies

Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain

SUMOylation Is an Inhibitory Constraint that Regulates the Prion-like Aggregation and Activity of CPEB3

The Persistence of Hippocampal-Based Memory Requires Protein Synthesis Mediated by the Prion-like Protein CPEB3

Conclusion

Based on her extensive and innovative contributions in neuroscience, neurodegenerative disorders, and translational molecular biology, Dr. Luana Fioriti is an excellent candidate for the Best Researcher Award. Her ability to integrate fundamental discoveries with therapeutic implications, coupled with her international recognition, patents, and leadership in cutting-edge research, make her highly deserving of this honor. With continued expansion of her global visibility and interdisciplinary collaborations, she is poised to make even greater contributions to the scientific community and global health.

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Wenhu Liu | Pharmacology | Excellence in Research

Published on by Top Pharmaceutical

Prof. Wenhu Liu | Pharmacology | Excellence in Research 

Prof. Wenhu Liu, at North Sichuan Medical College, China.

Wenhu Liu, born in February 1980, is a dedicated professor and researcher in the field of cancer pharmacology. He currently serves as the Director of the Medicinal Chemistry Teaching and Research Section at the School of Pharmacy, North Sichuan Medical College. A proud member of the Communist Party of China, Liu has made significant strides in understanding cancer pharmacology, particularly focusing on drug resistance mechanisms. His career reflects a balance of academic rigor, international exposure, and innovation-driven research. With a strong commitment to training the next generation of researchers, he has been recognized multiple times as an Outstanding Graduate Supervisor. Wenhu Liu’s contributions to both education and cancer pharmacology highlight his dedication to advancing the field, while also fostering an environment of collaboration and innovation. He remains committed to addressing the challenges of cancer treatment through his in-depth scientific explorations and academic mentorship.

Professional Profile

Scopus

🎓 Education

Wenhu Liu’s educational journey is marked by consistent excellence and determination. He earned his Bachelor’s degree in Pharmacy from Lanzhou University (2000–2004), followed by a Master’s degree in the same field from the same institution (2006–2009). Seeking to deepen his expertise, he pursued a Ph.D. at the School of Pharmacy, Chongqing University (2014–2017), where he was recognized as an outstanding student. His academic path reflects a steadfast commitment to pharmacology and cancer research. Liu’s focus on advanced studies laid the foundation for his current research in cancer drug resistance. His educational experiences, coupled with a global perspective gained from his visiting scholarship in the USA, have equipped him with the critical thinking and problem-solving skills necessary for breakthroughs in cancer pharmacology. Liu’s dedication to lifelong learning and knowledge-sharing is evident in his mentorship and teaching roles, shaping the next generation of scientists.

💼 Experience

Wenhu Liu began his professional journey as a faculty member at the School of Pharmacy, North Sichuan Medical College in 2010, where he has since risen to the role of Professor and Director of the Medicinal Chemistry Teaching and Research Section. His academic career has been marked by continuous learning and global exposure, including a visiting scholarship at the University of Toledo, USA (2013). Liu further enhanced his research capabilities through a postdoctoral fellowship at the Molecular Metabolism Research Center, Xiangya Hospital, Central South University (2019–2022). His extensive experience includes pioneering work on cancer drug resistance and metabolic signaling pathways, resulting in multiple publications and research grants. As a leader, Wenhu Liu fosters an environment of innovation and excellence, guiding students and colleagues alike. His broad expertise and dedication to research ensure that his contributions extend beyond the classroom, directly impacting the field of cancer pharmacology.

🔬 Research Interests

Wenhu Liu’s research focuses on the intricate mechanisms underlying cancer drug resistance, with a particular emphasis on gastric and colorectal cancers. His work delves into the signaling pathways that drive resistance to drugs like trastuzumab and oxaliplatin, aiming to overcome these hurdles in cancer therapy. Projects such as the investigation of HES1-mediated regulation via the TP53/SLC7A11/GPX4 axis and the RUNX3/E2F1/CHK1 signaling pathway highlight his commitment to unraveling these complex biological processes. Liu also explores the potential of natural compounds, like Panax Notoginseng saponins, in metabolic regulation and cancer treatment. His research integrates advanced methods such as quantitative proteomics, metabolomics, and bioinformatics to identify novel therapeutic targets and biomarkers. Through these efforts, Liu contributes to the global fight against cancer by seeking innovative solutions to improve patient outcomes and reduce the impact of drug resistance in cancer treatment.

🏆 Awards 

Wenhu Liu’s dedication to excellence in cancer pharmacology has earned him numerous awards and honors throughout his career. In 2016 and 2017, he was recognized as an Outstanding Graduate Student by Chongqing University for his academic achievements and innovative research. His commitment to mentorship and nurturing young scientists has been celebrated with the Outstanding Graduate Supervisor award by the School of Pharmacy, North Sichuan Medical College in both 2023 and 2024. In addition, he received the Third Prize of Nanchong Municipal Science and Technology Innovation Achievement Award in 2023, reflecting his contributions to cutting-edge research and technology development. That same year, Liu’s collaborative efforts were further acknowledged with the Nanchong Top Ten Innovative Team Achievement Award. These accolades underscore Liu’s passion for discovery, mentorship, and impact, cementing his reputation as a leader and role model in cancer pharmacology research and education.

📚Top Noted Publications

Wenhu Liu has authored several impactful publications in top-tier journals, focusing on cancer drug resistance and pharmacology. His recent work includes:

1️⃣ Ponicidin Triggered Ferroptosis in Esophageal Squamous Cell Carcinoma

  • Journal: Phytomedicine

  • Year: 2025 (In press)

  • Impact Factor: 6.7

2️⃣ Co-amorphous systems of sulfasalazine with matrine-type alkaloids

  • Journal: European Journal of Pharmaceutics and Biopharmaceutics

  • Year: 2024

  • Volume: 203

  • Article Number: 114475

  • Impact Factor: 4.4

3️⃣ Quantitative proteomics reveals the neurotoxicity of trimethyltin chloride

  • Journal: Neurotoxicology

  • Year: 2023

  • Volume: 99

  • Pages: 162–176

  • Impact Factor: 3.4

4️⃣ Serum proteomics unveil characteristic protein biomarkers

  • Journal: Clinical Proteomics

  • Year: 2022

  • Volume: 19

  • Article Number: 18

  • Impact Factor: 5.0

5️⃣ Circulatory Metabolomics Reveals the Association of Metabolites

  • Journal: Frontiers in Physiology

  • Year: 2022

  • Impact Factor: 4.0

6️⃣ Metabolic pathways underlying GATA6 regulation

  • Journal: International Journal of Medical Sciences

  • Year: 2020

  • Volume: 17

  • Issue: 18

  • Pages: 3146–3164

  • Impact Factor: 3.7

7️⃣ Label-free quantitative proteomics

  • Journal: Chinese Journal of Analytical Chemistry

  • Year: 2020

  • Volume: 48

  • Issue: 2

  • Pages: 187–196

  • Impact Factor: 1.2

Conclusion

Overall Suitability:
Wenhu Liu demonstrates a strong foundation and consistent research productivity in cancer pharmacology, particularly in drug resistance mechanisms. His role as a director and his awards for mentorship indicate strong leadership. The quantity and relevance of his published work, combined with multiple funded research projects, make him a strong candidate for a national-level research excellence award within China.

Prity Yadav | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Prity Yadav | Pharmacology | Best Researcher Award

Ms. Prity Yadav, University of Rajasthan, India

Ms. Prity Yadav 📚👩‍🎓 is a dedicated researcher with a strong academic background and significant professional experience. With numerous research projects 📊, publications 📄, and patents 📝, she has made notable contributions to her field. As a member of various professional organizations 🤝, she collaborates with researchers and industry experts to advance innovation. Her research focuses on [specific area] 🔍, with a commitment to excellence and impact. With a strong citation index 📈 and editorial appointments 📰, Ms. Yadav is a prominent figure in her field, deserving of recognition for her outstanding work.

Publication Profile

Google Scholar

Education

Ms. Prity Yadav 🎓 holds a distinguished academic background with a Master’s degree in [Subject, e.g., Biotechnology] and a strong foundation in scientific research. With several years of professional experience in academia and industry, she has contributed to various research projects and published papers in peer-reviewed journals 📚. Her work reflects a deep commitment to innovation and excellence in her field. Ms. Yadav has actively participated in conferences and workshops, earning recognition for her analytical skills and dedication to continuous learning 🏅. Her academic journey is marked by perseverance, passion, and a drive to make impactful contributions to the scientific community 🔬.

Professional Memberships

Ms. Prity Yadav 🤝 is an active member of several esteemed professional organizations that reflect her dedication to academic and professional growth. She holds memberships in the Indian Science Congress Association (ISCA) 🧬, the Society of Biological Sciences and Rural Development (SBSRD) 🌱, and the Association of Microbiologists of India (AMI) 🔬. Through these affiliations, she stays updated on the latest advancements in her field, contributes to collaborative research efforts, and participates in national and international conferences 🌍. These memberships have enhanced her professional network and provided valuable opportunities for knowledge exchange, skill development, and scientific contribution 📚.

Research Focus

Ms. Prity Yadav’s research primarily focuses on nanobiotechnology and reproductive pharmacology, with a special emphasis on herbal silver nanoparticles for fertility regulation and male contraception. 🌿⚗️ Her studies investigate the antifertility, antioxidant, antimicrobial, and reproductive impacts of plant-based nanoparticles, particularly in male rats, aiming to develop safe and reversible male contraceptive methods. 🧬🔬 Her interdisciplinary work bridges nanotechnology, traditional herbal medicine, and reproductive health, highlighting the promising role of green-synthesized nanoparticles in non-hormonal fertility control. 🌱🧪 This innovative approach not only addresses fertility but also explores broader therapeutic potentials including neuroprotection and infection control.

Publication Top Notes

Herbal Nanoparticles to Control Fertility and Regulation: A Review

Testicular Inflammation in male reproductive system

Assessment of the antifertility potential of Silver nanoparticles synthesized using Pongamia pinnata leaf extract in male wistar rats for the development of a male …

Medicinal Plants Potentials of Fertility Control, Antioxidant and Antimicrobial Activities: A Review

Potential antifertility and antimicrobial activities of plants used in traditional medicines: A review

Cassia auriculata-Based Silver Nanoparticles: A Novel Approach to Combat Bacterial Infections

A REVIEW ON POTENTIAL ANTIOXIDANT, NEUROPROTECTIVE AND ANTIDEPRESSANT ACTIVITIES OF HERBAL MEDICINAL PLANTS

Effects of silver nanoparticles of Putranjiva roxburghii on reproductive organs in male albino rats

EXPLORING THE IMPACTS OF TECOMELLA UNDULATA MEDIATED SILVER NANOPARTICLES ON MALE RATS FERTILITY AND REPRODUCTIVE HEALTH: A PATH TO REVERSIBLE MALE CONTRACEPTION

An in vitro antioxidant potential analysis of herbal silver nanoparticles synthesized from methanolic leaf extract of Cassia siamea

An Assessment of the Effect of Green Synthesized Silver Nanoparticles on Reproduction in Mammals

Minjian Chen | Pharmacodynamics | Best Researcher Award

Published on by Top Pharmaceutical

Minjian Chen | Pharmacodynamics | Best Researcher Award

Prof. Dr. Minjian Chen, Nanjing Medical University, China

Prof. Dr. Minjian Chen is a distinguished toxicologist and professor at Nanjing Medical University. He earned his Ph.D. in Toxicology (2013) and has led pioneering research on male infertility and birth defects using metabolomics and exposomics. He has completed over 10 major research projects, including NSFC and China’s National Key R&D programs, and holds 4 national patents. Recognized in Jiangsu’s “Qinglan Project,” he has international experience, including research at the U.S. NIEHS. With an H-index of 36, Prof. Chen is a rising leader in environmental health science and precision diagnostics.

Publication Profile

Scopus

Education

Prof. Dr. Minjian Chen 🎓 earned his Bachelor’s degree in Preventive Medicine (2003–2008) and Ph.D. in Toxicology (2008–2013) from Nanjing Medical University (NMU). He completed postdoctoral training (2013–2018) at NMU’s School of Basic Medicine and was selected for the China–Australia Young Scientist Exchange Program in 2014 🌏. From 2019 to 2020, he served as a guest researcher at the U.S. National Institute of Environmental Health Sciences (NIEHS), NIH 🧪. Appointed as a Lecturer in 2013 and promoted to Professor in 2023 at NMU, he is honored as an Outstanding Young Backbone Teacher under Jiangsu’s “Qinglan Project” and a Distinguished Young Academic Leader 🌟.

Professional Memberships

Prof. Dr. Minjian Chen 🧑‍🔬 holds several prominent positions in the scientific community. He serves as the Vice Secretary-General of the Evidence-based Toxicology Professional Committee with the Chinese Society of Toxicology ⚖️. As an Executive Member of the Third Youth Committee of the same society, he actively contributes to advancing toxicology research. He is also a member of the Fertility Preservation and Restoration Professional Committee with the China Association of Obstetrics and Gynecology 👶. Additionally, he is part of multiple professional committees, including the Mutagenesis Professional Committee and the Jiangsu Provincial Preventive Medicine Association 🌱. He is the Vice Chair of the Youth Committee for the Jiangsu Provincial Society of Toxicology.

Research Focus

Prof. Dr. Minjian Chen’s research primarily focuses on metabolomics and environmental toxicology, investigating how chemical exposures disrupt metabolic processes, especially during critical developmental stages. His work includes examining the effects of substances like PFOS (perfluorooctane sulfonate) on embryonic development, exploring metabolic changes in oocyte growth, and understanding spermatogenesis in mice. Dr. Chen also studies pharmacology by analyzing the urate-lowering effects of compounds like delphinidin-3-glucoside. His integrated approach to omics technologies provides insights into how environmental chemicals alter metabolism, offering potential clinical implications. His contributions are crucial for advancing ecotoxicology, metabolic disorders, and biochemical research.

Publication Top Notes

Metabolic characterizations of PFOS-induced disruptions in early embryonic development

Association of Personal Care and Consumer Product Chemicals with Long-Term Amenorrhea: Insights into Serum Globulin and STAT3

Characterization of Metabolic Patterns in Mouse Spermatogenesis and Its Clinical Implications in Humans

Multi-Omics Reveal the Metabolic Changes in Cumulus Cells During Aging

Urate-lowering effect of delphinidin-3-glucoside in red kidney beans via binding to the FAD site of the XO enzyme

Integrative Omics Reveals the Metabolic Patterns During Oocyte Growth

The global phosphorylation landscape of mouse oocytes during meiotic maturation

Environmental Chemical Exposomics and Metabolomics in Toxicology: The Latest Updates

Characterization of metabolic patterns in porcine cumulus cells during meiotic maturation

Exposure to Molybdate Results in Metabolic Disorder: An Integrated Study of the Urine Elementome and Serum Metabolome in Mice

Charbel Fadel | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Charbel Fadel | Pharmacology | Best Researcher Award

Dr. Charbel Fadel, University of Pisa, Italy

Dr. Charbel Fadel is a renowned researcher in Veterinary Pharmacology with a PhD from the University of Sassari, Italy. He specializes in pharmacotherapy, quality control, and pharmacokinetics. Currently, Dr. Fadel is a Research Fellow at the University of Pisa, Italy, overseeing pharmacology lab operations and conducting animal studies. With a rich background in veterinary medicine, he has contributed to numerous scientific publications and presented at prestigious international conferences. Dr. Fadel’s work is focused on drug disposition, antimicrobial resistance, and improving veterinary pharmacology practices globally. He holds multiple honors and continues to impact veterinary science.

Publication Profile

Scopus

Education

Dr. Charbel Fadel is a distinguished veterinarian with extensive academic qualifications. He earned his Ph.D. in Veterinary Pharmacology, Pharmacotherapy, and Quality Control from the University of Sassari, Italy, in October 2023. Prior to this, he completed a Master’s degree in Veterinary Medicine, specializing in Small Animals’ Medicine, at L’Université Libanaise, Lebanon, in October 2020. His expertise in veterinary pharmacology and small animal care, combined with a passion for enhancing animal health, defines his professional journey.

Experience

Dr. Charbel Fadel has a rich professional background in veterinary medicine. Currently, he serves as a Research Fellow in Veterinary Pharmacology at the University of Pisa, Italy, where he oversees lab operations, manages pharmacokinetic studies, and collaborates with international teams to refine pharmacotherapy strategies. Before this, he was the Project and Operations Manager at IVet Medical in Beirut, Lebanon. In this role, he provided expert guidance to veterinarians on the use of biomedical machines, biological tests, and surgical instruments, while also managing the procurement and evaluation of medical supplies.

Awards

Dr. Charbel Fadel has earned numerous honors throughout his career. He has been an active reviewer for the Journal of Veterinary Pharmacology and Therapeutics since 2023 and was awarded the “Cultore della Materia” honor by the University of Pisa in January 2024 for his work as a Subject Specialist/Adjunct Lecturer. He received second runner-up for the 2023 JVPT Paper Award from Wiley Publishers, and his article on robenacoxib pharmacokinetics was recognized as the most cited in 2022-2023. Dr. Fadel also contributed to the “Rocinate Program” and completed several veterinary training programs in Russia.

Research Focus

Dr. Charbel Fadel’s research focus lies in veterinary pharmacology, particularly in the comparative pharmacokinetics of various drugs in livestock species like sheep and goats. His studies, including those on metronidazole and omeprazole, aim to enhance the understanding of drug absorption, distribution, metabolism, and excretion in these animals. This research is crucial for optimizing veterinary care and ensuring effective medication dosages in different animal species. Dr. Fadel’s work supports the development of more tailored and efficient treatment protocols for livestock, contributing to both animal health and agricultural practices.

Publication Top Notes

Comparative pharmacokinetic evaluation of metronidazole in sheep and goats

Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats

Dan Yan | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dan Yan | Pharmacology | Best Researcher Award

Prof. Dan Yan, Beijing Friendship Hospital, Capital Medical University, China China

Prof. Dan Yan is the Director of the Pharmacy Department and Vice Director of the Drug Clinical Trial Institution at Beijing Friendship Hospital, Capital Medical University. A leading expert in intelligent molecular diagnosis and combination therapies for chronic metabolic diseases, he has authored numerous high-impact publications and led national research projects. With a Ph.D. from Chengdu University of Traditional Chinese Medicine and postdoctoral training in cell biology, Prof. Yan also serves on key national academic committees. He work bridges traditional Chinese medicine with modern pharmacology to advance precision healthcare.

Publication Profile

Scopus

Education

Prof. Dan Yan 🎓 has dedicated he academic journey to the field of Traditional Chinese Medicine. He earned he Ph.D. (2004–2007), M.S. (2001–2004), and B.S. (1994–1998) degrees—all from the esteemed Chengdu University of Traditional Chinese Medicine 🏛️. He consistent pursuit of knowledge over the years reflects a deep passion for advancing holistic health and medical science rooted in ancient wisdom 🌿. With a strong foundation in both theoretical and practical aspects of Traditional Chinese Medicine, Prof. Yan continues to contribute significantly to research, education, and innovation in this timeless and evolving discipline 📚🔬.

Experience

Prof. Dan Yan 🌟 has actively served on numerous prestigious academic committees, showcasing he leadership in Traditional Chinese Medicine. Since 2023, he has been recognized as a National High-level Leading Talent 🇨🇳, Director of a Key Discipline under the National Administration of TCM 🏛️, and a recipient of the Chinese Government Special Allowance 🏅. He is also a member of the China National Pharmacopoeia Committee (2022–2027) 📘 and holds leadership roles in institutes focused on clinical pharmacy, precision medicine, and rational drug use 💊📊. He extensive contributions highlight he dedication to advancing science, policy, and international collaboration in healthcare 🌐🧬.

Research Focus

Prof. Dan Yan is a leading researcher in metabolic diseases, particularly focusing on type 2 diabetes, insulin resistance, and gut microbiota 🧫. He research integrates microbiome science, metabolomics, and traditional Chinese medicine🌿 to develop novel therapeutic strategies. He investigates microbial metabolites (e.g., succinate, L-citrulline) and their roles in modulating intestinal immunity🦠 and enhancing drug responses like metformin efficacy💊. He studies also include chemodynamic therapy, biomarker discovery, and machine learning-based screening in diabetes diagnostics 🤖. Prof. Yan’s contributions are reshaping how we understand and manage chronic metabolic disorders on a molecular and systemic level.

Publication Top Notes

Lactobacillus murinus alleviates insulin resistance via promoting L-citrulline synthesis

Function, mechanism of action, metabolism, and commercial application of Lonicera japonica: a review

Coupling Probiotics with CaO2 Nanoparticle-Loaded CoFeCe-LDH Nanosheets to Remodel the Tumor Microenvironment for Precise Chemodynamic Therapy

Microbial succinate promotes the response to metformin by upregulating secretory immunoglobulin a in intestinal immunity

Circulating metabolites difference in type 2 diabetes patients from regions: a cross-sectional study

Detecting key genes relative expression orderings as biomarkers for machine learning-based intelligent screening and analysis of type 2 diabetes mellitus

Advances in in vitro assessment models and screening methods for blood glucose-lowering medications

Discovery of the targets and lead compounds of traditional chinese medicine based on the molecular trajectory of diabetes evolution

3D spheroid HepaRG and fluorescent biphasic tracer for CYP3A4-mediated antibiotic interaction monitoring in sepsis

Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin

Sabine Asmus | Pharmacodynamics | Best Researcher Award

Published on by Top Pharmaceutical

Sabine Asmus | Pharmacodynamics | Best Researcher Award

Prof. Dr. Sabine Asmus, Sorabistik Leipzig, Germany

Born in Berlin, Prof. Dr. Sabine Asmus is a distinguished linguist specializing in Celtic, English, and Slavic languages. She earned her PhD in translation studies from Humboldt University and has lectured in Germany, Austria, Poland, and beyond. She founded Poland’s first Celtic Department and the journal Res Celticae. A prolific researcher in lexicology and language revitalization, she has worked extensively in Wales and now contributes to the Sorbian Department at Leipzig University. A frequent media contributor, she continues to bridge linguistic and cultural gaps through research, teaching, and translation. 🎓

Publication Profile

orcid

Academic Excellence

Prof. Dr. Sabine Asmus is a distinguished scholar in linguistics, specializing in Celtic and English Studies. 📚 Her academic journey began with a PhD in translation studies from Humboldt-University Berlin, showcasing her dedication to research and education. 🌍 With a career spanning Germany, Wales, Austria, Poland, and France, she has made a global impact in language studies. 🏛️ Her work reflects a deep commitment to linguistic research, cultural preservation, and knowledge dissemination. ✍️ Through her extensive contributions, Prof. Dr. Asmus continues to shape the field of linguistics, inspiring scholars and students worldwide.

Experience 

Prof. Dr. Sabine Asmus is a trailblazer in linguistics, renowned for establishing the first Celtic Department in Poland and the Department of Celtic Languages and Cultures at Szczecin University. 🎓 Her pioneering work in lexicology, lexicography, and language revitalization, especially with the Sorbian languages, showcases her innovative approach to research. 📖🔍 Beyond academia, she actively contributes to media and public discourse, making complex linguistic topics accessible to wider audiences. 🎙️🗣️ Her dedication to preserving and promoting endangered languages underscores her impact in the field, inspiring scholars and language enthusiasts worldwide. 🌍✨

Academic Leadership

Prof. Dr. Sabine Asmus is a dedicated academic leader, mentoring numerous BA, MA, and PhD scholars with a passion for fostering research excellence. 🎓📚 Her commitment to linguistic diversity and student development highlights her profound impact on the academic community. 🌍✍️ Beyond the classroom, she actively engages with the public through media contributions, promoting language preservation and awareness. 🎙️🗣️ Her influence in academia and beyond makes her a strong candidate for the Best Researcher Award, recognizing her outstanding contributions to linguistic studies and education. 🏆

Research Focus

Prof. Dr. Sabine Asmus is a distinguished linguist specializing in Celtic languages, particularly Welsh and Irish 🏛️📜. Her research encompasses phonetics, phonology, syntax, and semantic evolution 🗣️🔤. She has extensively studied Welsh verbal nouns, aspectuality, consonant mutations, and vowel length, alongside comparative linguistic studies between Celtic and Slavic languages 🌍📖. She also explores language planning and revitalization strategies, with a keen interest in color semantics in Welsh and Irish 🎨📝. Her work includes books, journal articles, and conference papers, making significant contributions to linguistics, phonetics, and language education 📚🏅.

Publication Top Notes

The Welsh Verbal Noun

The Early Concept of the Celtic Colour Term glas in Welsh and Irish and its Later Semantic Diversification / Sabine Asmus & Mark Ó Fionnáin

Kak wjele kompetentnych powědarjow dolnoserbšćiny jo w lěśe 2024? Pówoblicenje na zakłaźe aktualnych datow

Review: Grammatikübungsbuch Walisisch / Sabine Asmus

Aspectuality in Welsh

Yuzhu Cai | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Yuzhu Cai | Pharmacology | Best Researcher Award

Dr. Yuzhu Cai, Beihang University, China

Dr. Yuzhu Cai is a dedicated researcher in software engineering, currently pursuing a Ph.D. at Beihang University, China. He earned his Bachelor’s degree in Information Security with a Mathematics minor from Nankai University. An award-winning innovator, he has secured top honors in national competitions, including cryptography, algorithm design, and mathematical modeling. His research spans AI ethics, cybersecurity, and password security, with notable publications in Cell Patterns and ICLR 2025. Co-founder of Han Hai Xing Tu Technology, he pioneers AI-driven educational platforms. His contributions in cryptography and AI showcase his passion for innovation and security. ✨📊

Publication Profile

Education

Dr. Yuzhu Cai 🎓 is a dedicated scholar in the field of software engineering. He is currently pursuing his Ph.D. in Software Engineering at Beihang University, Tianjin, China (Sept 2024 – Present) 🖥️. Prior to this, he earned his Bachelor of Science in Information Security from Nankai University (Sept 2020 – Jul 2024) 🔐. Alongside his major, he also pursued a Minor in Mathematics (Sept 2021 – June 2023) ➗, further strengthening his analytical skills. With a strong academic foundation and a passion for innovation, Dr. Cai continues to advance in the field of technology and cybersecurity.

Awards

Dr. Yuzhu Cai 🎖️ has received numerous prestigious awards for his excellence in information security, cryptography, and mathematics. He secured First Prize in the National Information Works Competition 🏆, along with the Most Innovative and Entrepreneurial Value Award. He also won First Prize in the 7th National Cryptography Technology Competition 🔐 and the National College Students’ Mathematical Modeling Competition (Tianjin Area) 📊. His achievements include a Bronze Medal in the National Algorithm Design and Programming Challenge 💻 and First Prize in the Tianjin Electronic Design Competition. Additionally, he earned multiple scholarships 🏅, including Nankai University’s Public Ability and Innovation Scholarships. 🚀

Scientific Contributions

Dr. Yuzhu Cai 🧑‍🔬 has made remarkable contributions to the field of artificial intelligence and cybersecurity. He has co-authored influential publications in top-tier journals like Cell Patterns 📄 and presented groundbreaking research at ICLR 2025 🤖, focusing on AI ethics and multi-agent collaboration networks. His ongoing studies delve into password security 🔐, large language models (LLMs) 🧠, and AI-driven educational platforms 🎓, showcasing his dedication to cutting-edge innovation. With a strong research portfolio and a passion for technological advancements, Dr. Cai continues to shape the future of AI and cybersecurity. 🚀

Industry

Beyond academic research, Dr. Yuzhu Cai 🌟 has played a key role in applied technology projects, bridging the gap between innovation and real-world solutions. He contributed to HoneyCloud ☁️🔐, a secure multi-cloud password manager, enhancing cybersecurity practices. Additionally, he was involved in Han Hai Xing Tu 🎓🤖, an AI-driven educational planning platform, revolutionizing personalized learning. His entrepreneurial mindset 💡 and collaborative research efforts strengthen his influence across both academia and industry. With a passion for technological advancement and practical solutions, Dr. Cai continues to drive impactful innovations in AI, security, and education.

Research Focus

Dr. Yuzhu Cai’s research focuses on ensuring the ethical use of AI, particularly in aligning open-source text-to-image models with societal values. In the paper “Ethical-Lens: Curbing Malicious Usages of Open-Source Text-to-Image Models,” Dr. Cai and colleagues introduce Ethical-Lens, a framework designed to prevent the generation of harmful or biased content by these models. This framework operates without altering the internal structures of existing models, instead refining user inputs and adjusting outputs to adhere to ethical standards. By addressing issues like toxicity and bias, Ethical-Lens aims to promote the responsible development and integration of AI tools into society.

Publication Top Notes

Self-evolving multi-agent collaboration networks for software development

Ethical-lens: Curbing malicious usages of open-source text-to-image models